1. Home
  2. JBLU vs PTGX Comparison

JBLU vs PTGX Comparison

Compare JBLU & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$4.46

Market Cap

2.1B

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$144.66

Market Cap

9.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
PTGX
Founded
1998
2006
Country
United States
United States
Employees
N/A
141
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
9.3B
IPO Year
2002
2016

Fundamental Metrics

Financial Performance
Metric
JBLU
PTGX
Price
$4.46
$144.66
Analyst Decision
Sell
Strong Buy
Analyst Count
13
13
Target Price
$4.91
$108.23
AVG Volume (30 Days)
17.9M
470.3K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
N/A
EPS
N/A
2.35
Revenue
$9,062,000,000.00
N/A
Revenue This Year
$12.11
$874.25
Revenue Next Year
$6.75
N/A
P/E Ratio
N/A
$61.10
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$62.24
52 Week High
$6.62
$160.81

Technical Indicators

Market Signals
Indicator
JBLU
PTGX
Relative Strength Index (RSI) 40.33 48.34
Support Level $3.87 $141.95
Resistance Level $5.12 $151.24
Average True Range (ATR) 0.15 4.91
MACD 0.02 -0.81
Stochastic Oscillator 50.00 39.10

Price Performance

Historical Comparison
JBLU
PTGX

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: